Browsing by Author "Ozdemir, T"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    10 Years of Antenatal Hydronephrosis Experience: Comparing Two Different Guidelines
    Ensari, E; Yavascan, O; Alparslan, C; Oncel, EP; Maden, AA; Demir, BK; Alaygut, D; Ozdemir, T
    Background Antenatal hydronephrosis refers to the dilation of the renal pelvis and/or calyces in the developing fetus. The challenge lies in distinguishing between cases that warrant long-term follow-up or surgical intervention and those with transient hydronephrosis that require minimal invasive investigations. Materials and Methods Our study aimed to assess and contrast the efficacy of the 2015 Congenital Anomalies of Kidney and Urinary Tract Guideline from the Turkish Society of Pediatric Nephrology with the Tepecik Antenatal Hydronephrosis Guideline, which was previously employed in our hospital. We conducted a comparative analysis of demographic data, outcome conditions, additional imaging requirements and quantities, radiation exposures, and rates of surgical interventions between two groups. Results Group 2 had a significantly higher detection rate of Vesicoureteral Reflux via voiding cystourethrogram at 38.5% compared to Group 1's 13.4% (p<0.01). The incidence of abnormal findings with dimercaptosuccinic acid was similar between Group 1 (28.5%) and Group 2 (26.4%) (p>0.01), but Group 2 had a higher rate of obstruction diagnosis at 68.8% versus Group 1's 29.4% (p<0.01). Group 1 had greater median radiation exposure (500 mrem vs. 200 mrem, p<0.01), and a higher proportion of patients underwent surgery (34.2% vs. 21.9%, p<0.01). Conclusion This study showed that the new guideline required fewer tests, was less invasive, and exposed patients to less radiation than the old guideline.
  • No Thumbnail Available
    Item
    Mechanisms and grading of nocturia: Results from a multicentre prospective study
    Bozkurt, O; Irer, B; Kizilay, F; Erbatu, O; Sen, V; Cinar, O; Ongun, S; Cihan, A; Ozdemir, T; Tasdemir, D; Ucer, O
    Objective To identify the pathophysiological mechanisms of nocturia and the correlation of these mechanisms with nocturia severity. Methodology After approval by the local ethics committee, all patients with nocturia (>= 1 nocturnal void/night) were included and filled the Overactive Bladder questionnaire, Nocturia Quality of Life, Incontinence Questionnaire - Male Lower Urinary Tract Symptoms (male), International Consultation on Incontinence Questionnaire - Female Lower Urinary Tract Symptoms (female) and 3-day frequency-volume chart. Patients were divided into three groups according to the severity of nocturia: group 1 consisted of patients with mild (1-2 voids/night), group 2 with moderate (3-4 voids/night) and group 3 with severe nocturia (>4 voids/night). Comparative analysis was performed between groups, andP About 68.1%, 64.1% and 8.7% of the patients had nocturnal polyuria (NP), reduced bladder capacity and global polyuria, respectively. 42.7% of the patients had mixed nocturia. 6.1% of the patients did not comply with the aforementioned subtypes and defined as isolated nocturia. Regarding the severity of nocturia, 155 (41%) patients had mild, 167 (45%) patients had moderate and 57 (15%) patients had severe nocturia. Increased nocturia severity was related with decreased quality of life; higher age, urinary tract symptom scores, nocturnal urine volume, evening fluid consumption and beta-blocker medication rates. Increased nocturia severity was also associated with higher NP, global polyuria and reduced bladder capacity rates. Conclusions Nocturia mechanisms may vary between mild and moderate to severe nocturia groups according to the present study. Nocturia grading with identification of subtypes may help for better standardisation of the diagnostic and treatment approaches as well as for the design of future clinical trials.
  • No Thumbnail Available
    Item
    Effects of mirabegron on JJ stent-related symptoms: A multicentric study
    Cinar, O; Tanidir, Y; Ozer, S; Cizmeci, S; Erbatu, O; Ozdemir, T; Girgin, R; Ongun, S; Ucer, O; Kizilay, F; Sen, V; Irer, B; Bozkurt, O
    Aims of the study To investigate the effect of mirabegron 50 mg/daily for JJ stent-related symptoms after ureteroscopic stone surgery. Methods Medical records of 145 patients who were given a single daily oral dose of 50 mg of mirabegron for relieving stent-related symptoms were retrospectively analysed. Demographic and clinical data and stone parameters were recorded. All participants completed the Turkish version of the Ureter Symptom Score Questionnaire (USSQ-T) on the postoperative 7th day, and again after at least 3 weeks, before JJ stent removal. The severity of stent-related symptoms was statistically compared before and after the mirabegron treatment. Results The mean urinary symptoms score decreased significantly from 30.87 +/- 9.43 to 22.61 +/- 6.78 (P < .0001), mean body pain score decreased significantly from 21.82 +/- 11.22 to 14.03 +/- 7.52 (P < .0001), mean work performance score decreased from 10.50 +/- 8.61 to 7.02 +/- 6.51 (P < .0001) and mean general health score decreased significantly from 15.43 +/- 6.50 to 11.12 +/- 3.70 (P < .0001). The mean sexual matters score significantly decreased from 3.88 +/- 3.40 to 2.48 +/- 2.03 (P < .0001), the additional problem score decreased from 9.31 +/- 4.61 to 6.51 +/- 2.83 (P < .0001) and the overall quality of life (QoL) score decreased from 5.18 +/- 1.94 to 4.23 +/- 1.71 after mirabegron use (P < .0001). Conclusion Daily use of 50 g of mirabegron significantly improved stent-related symptoms, sexual matters and quality of life.